UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant specified in its charter)
(State or Other Jurisdiction Of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On December 31, 2021, Cushman & Wakefield plc (the “Company”) and Cushman & Wakefield Global, Inc. entered into a side letter agreement (the “Side Letter”) with Brett White, the Executive Chairman of the Company’s Board of Directors (the “Board”), in connection with Mr. White’s previously announced resignation as Chief Executive Officer of the Company. Pursuant to the terms of the Side Letter, Mr. White’s resignation is confirmed as a Qualifying Resignation as defined under Mr. White’s Amended and Restated Employment Agreement (the “Employment Agreement”), dated as of August 27, 2020, which Qualifying Resignation accelerates and vests certain of Mr. White’s equity awards in accordance with the terms of the Employment Agreement. Following the Qualifying Resignation, the Company has no obligation to provide any additional salary or bonus to Mr. White, except that he remains eligible to receive his Annual Bonus (as defined in the Employment Agreement) for the 2021 calendar year. The Side Letter also extends the restrictive covenants in the Employment Agreement to apply to Mr. White through June 30, 2025; however, Mr. White is permitted to participate in certain non-competitive activities outside of the Company.
This summary of the Side Letter does not purport to be complete and is qualified in its entirety by the text of the Side Letter, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are filed as part of this report:
Exhibit # | Description | |
10.1 | Side Letter, dated December 31, 2021, by and among Cushman & Wakefield Global, Inc., Cushman & Wakefield plc and Brett White | |
104 | Cover Page Interactive Data file (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 4, 2021 | CUSHMAN & WAKEFIELD PLC | |||||
By: | /s/ Brett Soloway | |||||
Name: Brett Soloway | ||||||
Title: Executive Vice President, General Counsel and Corporate Secretary |
Exhibit 10.1
SIDE LETTER AGREEMENT
This Side Letter Agreement (this Side Letter), is made and entered into as of December 31, 2021, by and among Cushman & Wakefield Global, Inc. (the Employer), Cushman & Wakefield plc (together, as the context requires, with the Employer and their respective subsidiaries, affiliates, predecessors, successors and assigns, the Company) and Brett White (Executive). The Company and Executive are each referred to herein individually as a Party and together as the Parties. Capitalized terms used and not defined herein shall have the meanings given to such terms in the Employment Agreement (as defined below).
WHEREAS, the Parties entered into that certain Amended and Restated Employment Agreement, dated as of August 27, 2020 (the Employment Agreement), which sets forth the terms and conditions governing Executives employment with the Company;
WHEREAS, in accordance with the terms of the Employment Agreement, the Parties intend that Executive will incur a Qualifying Resignation, effective as of December 31, 2021 (the Effective Date); and
WHEREAS, the Parties now desire to enter into this Side Letter to set forth their understanding with respect to certain terms and conditions upon and following the Qualifying Resignation.
NOW, THEREFORE, in consideration of the mutual covenants, commitments and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1. Restrictive Covenants. Executive acknowledges and agrees that the rights and obligations set forth in Section 4 of the Employment Agreement (collectively, and as modified herein, the Restrictive Covenants) will remain in full force and effect in accordance with all of the terms and conditions thereof, except as expressly set forth in this Section 1.
(a) Extension of Restricted Periods. Notwithstanding any provision of the Employment Agreement or any other agreement between the Parties to the contrary, the Restrictive Covenants shall survive the Effective Date and continue to apply during Executives service as a member of the Board of Directors; provided that the Restrictive Covenants set forth in Section 4.1 of the Employment Agreement shall survive the Effective Date and expire on June 30, 2025, regardless of the date that Executive ceases to provide services to the Company (either as an employee or as a member of the Board of Directors).
(b) Outside Activities Exception. Following the Effective Date, Executive shall not be required to obtain the prior written consent of the Board of Directors in order to, and Executive may, provide services in any capacity to a for-profit entity, organization or business other than the Company, (i) so long as such entity, organization or business is not publicly traded and (ii) subject to Executives continued compliance with the other provisions set forth in Sections 1.3 and 4 of the Employment Agreement (including, for the avoidance of doubt and without limitation, with respect to any Competing Business or any other entities, organizations, businesses or activities that compete or are competitive with the Company). For the avoidance of doubt, the restrictions set forth in Section 1.3 of the Employment Agreement (as modified by this Section 1(b)) and subject to the limitations of the Restrictive Covenants) shall expire on the earlier to occur of (x) the date that Executive is no longer providing services to the Company, either as an employee or as a member of the Board of Directors, and (y) December 31, 2023.
The Parties acknowledge and agree that the consideration provided to Executive (A) upon the Qualifying Resignation and (B) in Sections 1(b) and 2 of this Side Letter is sufficient consideration for the Restrictive Covenants, as modified herein.
2. No Additional Compensation or Benefits. Except as expressly set forth in Section 3.7 of the Employment Agreement and except for (a) any vested benefits under any Company plans and (b) the continuation of health insurance benefits (i) for the period during which Executive continues to be employed by the Company or (ii) if not so employed, on the terms and to the extent required by COBRA, the Company shall have no additional obligations upon and following the Effective Date with respect to any compensation or benefits payable to Executive, including with respect to any Base Salary and Annual Bonus amounts and severance benefits, except that (x) Executive shall remain eligible to receive any Annual Bonus in respect of calendar year 2021 based on achievement of the performance goals previously established by the Board of Directors (or a committee thereof) for such calendar year, to be paid at the same time as annual bonuses in respect of calendar year 2021 are paid to other senior executives of the Company, and in accordance with Section 2.2 of the Employment Agreement, and (y) if Executives service on the Board of Directors continues beyond December 31, 2023, then, commencing on January 1, 2024, Executive shall be entitled to receive any non-employee director compensation and benefits made available to the Companys other non-employee directors then serving on the Board of Directors in accordance with the Companys non-employee director compensation program as in effect from time to time. Notwithstanding the foregoing and for the avoidance of doubt, no provision of this Side Letter shall be construed to alter Executives eligibility to receive any remaining Equity Grants in accordance with Sections 2.4(a) and 3.7 of the Employment Agreement.
3. General Provisions.
(a) Except as expressly provided herein, the Parties acknowledge and agree that the terms of the Employment Agreement and the Restrictive Covenants shall otherwise remain unchanged, and the Parties shall remain subject to all of the terms and conditions set forth therein. Executive acknowledges and agrees that Executives execution of and entry into this Side Letter were voluntary and shall not constitute or provide a basis, in any part, for Good Reason under the Employment Agreement or any other agreement between the Parties.
(b) Sections 5.1 through 5.7 and Sections 5.9 through 5.16 of the Employment Agreement are hereby incorporated into this Side Letter by reference thereto, mutatis mutandis. No other agreements or representations with respect to the subject matter hereof have been made by either Party that are not expressly set forth in the Employment Agreement or this Side Letter, and this Side Letter and the Employment Agreement, as modified herein, set forth the entire understanding and agreement between the Parties with respect to the subject matter contained herein. In the event of any conflict between the Employment Agreement or any other agreement between the Parties and this Side Letter, this Side Letter shall control.
[Signature Page Follows]
2
IN WITNESS WHEREOF, the undersigned have executed this Side Letter Agreement as of the date and year first written above.
CUSHMAN & WAKEFIELD GLOBAL, INC. | EXECUTIVE | |
By: /s/ Brett Soloway |
/s/ Brett White | |
Name: Brett Soloway |
Brett White | |
Title: Director |
||
CUSHMAN & WAKEFIELD PLC | ||
By: /s/ Tim Dattels |
||
Name: Tim Dattels |
||
Title: Lead Director |
Side Letter Agreement Signature Page
Document and Entity Information |
Dec. 31, 2021 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001628369 |
Document Type | 8-K |
Document Period End Date | Dec. 31, 2021 |
Entity Registrant Name | Cushman & Wakefield plc |
Entity Incorporation State Country Code | X0 |
Entity File Number | 001-38611 |
Entity Tax Identification Number | 98-1193584 |
Entity Address, Address Line One | 125 Old Broad Street |
Entity Address, City or Town | London |
Entity Address, Country | GB |
Entity Address, Postal Zip Code | EC2N 1AR |
City Area Code | +44 |
Local Phone Number | 20 3296 3000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Ordinary shares, $0.10 nominal value |
Trading Symbol | CWK |
Security Exchange Name | NYSE |
Entity Emerging Growth Company | false |
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end